touchPODCAST

touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchONCOLOGY

What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights.

The multidisciplinary team

Medical oncologist – Dr Jacob Sands
Dana-Farber Cancer Institute, Boston, MA, USA

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

touchMDT for touchONCOLOGY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks, 
Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

Vaccination strategies for pneumococcal disease

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES

In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections.

The expert

• Prof. Antoni Torres, University of Barcelona, Spain

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchINFECTIOUS DISEASES.com 

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti
• Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting
2. Approved and emerging TKIs for CML in the second- and later-line settings
3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy
• Prof. Susanne Saussele: Mannheim, Germany
• Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

touchCONGRESS for touchHAEMATOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti
• Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting
2. Approved and emerging TKIs for CML in the second- and later-line settings
3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy
• Prof. Susanne Saussele: Mannheim, Germany
• Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC

Pharmacological management of agitation in Alzheimer's dementia

touchPANEL DISCUSSION for touchNEUROLOGY

Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology. 

The experts

• Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA 
• Prof. Krista Lanctôt, University of Toronto, ON, Canada 
• Prof. James Galvin, University of Miami, FL, USA 

 

This touchPODCAST is for HCPs outside of the UK only. 

This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA).

For further information visit:

https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/ 

 

touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO

touchIN CONVERSATION for touchCARDIO

Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape. 

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

The experts

• Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA
• Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium 

For further information visit our website: 

www.touchCARDIO.com 

touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY

touchIN CONVERSATION for touchRESPIRATORY

Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape. 

This touchPODCAST is for HCPs outside of the UK.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

The experts

• Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USA
• Prof. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium 

For further information visit our website: 

www.touchRESPIRATORY.com 

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1

touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchONCOLOGY.com 

touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2

touchMDT for touchONCOLOGY

Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations.

The multidisciplinary team

• Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USA
• Interventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USA
• Clinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA
• Oncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USA
• Molecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: 

www.touchONCOLOGY.com